NASDAQ:SURF
Surface Oncology, Inc.
- Stock
locale
United Statesmarket
STOCKSindustry
Biotechnologywebsite
www.surfaceoncology.comipo date
Apr 19, 2018
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic a...Show More
Earnings
Earnings Release in 4 daysEarnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus